Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$12.20B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  ROIV
Roivant Sciences Ltd.
ROIV
68 / 100
$10.94arrow_drop_down3.10%-$0.35

Performance History

Stocklytics logo
Key Stats
Open$11.29
Prev. Close$11.29
EPS5.27
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$9.16B
PE Ratio2.08
LOWHIGH
Day Range10.86
11.29
52 Week Range8.24
13.24
Ratios
P/B Ratio1.45
Revenue$61.28M
Operating M. %-774.17%
Earnings$0.00
Earnings Growth %-20.71%
EBITDA Margin %-1,000.00%
ROE %105.80%
EPS5.27

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$808.45
24H (%)arrow_drop_up0.69%
24H ($)$5.54
MARKET CAP$744.33B
PRICE$516.83
24H (%)arrow_drop_down0.86%
24H ($)-$4.51
MARKET CAP$476.05B
PRICE$149.70
24H (%)arrow_drop_down2.47%
24H ($)-$3.80
MARKET CAP$364.05B
PRICE$131.09
24H (%)0.00%
24H ($)-$0.01
MARKET CAP$332.27B

About Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Matthew Gline
Headquarters
London
Employees
904
Exchange
NASDAQ
add Roivant Sciences Ltd. to watchlist

Keep an eye on Roivant Sciences Ltd.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Roivant Sciences Ltd.'s (ROIV) price per share?

The current price per share for Roivant Sciences Ltd. (ROIV) is $10.94. The stock has seen a price change of -$0.35 recently, indicating a -3.1% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Roivant Sciences Ltd. (ROIV)?

For Roivant Sciences Ltd. (ROIV), the 52-week high is $13.24, which is 21.02% from the current price. The 52-week low is $8.24, the current price is 32.69% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Roivant Sciences Ltd. (ROIV) a growth stock?

Roivant Sciences Ltd. (ROIV) has shown an average price growth of 0.41% over the past three years. It has received a score of 85 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Roivant Sciences Ltd. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Roivant Sciences Ltd. (ROIV) stock price performance year to date (YTD)?

As of the latest data, Roivant Sciences Ltd. (ROIV) has a year-to-date price change of -3.61%. Over the past month, the stock has experienced a price change of -0.82%. Over the last three months, the change has been -6.5%. Over the past six months, the figure is 20.22%.

help
Is Roivant Sciences Ltd. (ROIV) a profitable company?

Roivant Sciences Ltd. (ROIV) has a net income of -$1.12B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 78.58% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -774.17% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $61.28M, with a revenue growth rate of 10.84%, providing insight into the company's sales performance and growth. The gross profit is $48.15M. Operating income is noted at -$1.08B. Furthermore, the EBITDA is -$1.03B.

help
What is the market capitalization of Roivant Sciences Ltd. (ROIV)?

Roivant Sciences Ltd. (ROIV) has a market capitalization of $9.16B. The average daily trading volume is 3.35M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level